Figma Shares Indicated To Open $105/$110
Cosmos Holdings Inc. (COSM) stock has reached a new 52-week low, trading at $0.46. The company, with a market capitalization of $10.3 million, operates with an 8.1% gross profit margin and carries a significant debt burden, according to InvestingPro data. This latest price point underscores a challenging period for the company, which has seen its stock value decline significantly over the past year. The 52-week low serves as a stark indicator of the market’s current valuation of the company, reflecting investor sentiment and the stock’s performance in a competitive industry. Over the past year, Cosmos Holdings has experienced a substantial decrease in its stock value, with a 1-year change showing a -40.13% drop. With a beta of 3.64 and net losses of $33.81 million in the last twelve months, this downturn highlights the hurdles the company has faced, as well as the broader market conditions influencing stock prices. InvestingPro analysis suggests the stock may be undervalued at current levels, with 13 additional key insights available to subscribers.
In other recent news, Cosmos Health Inc. has delayed its planned securities offering, initially set to be conducted under its Registration Statement on Form S-1. This decision aligns with the company’s preparation to file its Annual Report on Form 10-K for the fiscal year ending December 31, 2024. In a separate development, Cosmos Health is advancing its weight management product, CCX0722, to clinical trials, anticipating completion between late 2025 and early 2026. The company is collaborating with Contract Research Organizations to finalize the technical dossier for regulatory submission.
Additionally, Cosmos Health has filed two new patent applications for treatments targeting glioma and hematologic malignancies, in partnership with Cloudpharm and the National Hellenic Research Foundation. This move underscores the company’s focus on expanding its intellectual property portfolio. Furthermore, Cosmos Health has secured a 10-year contract manufacturing agreement with Provident Pharmaceuticals through its subsidiary Cana Laboratories. This contract involves the production of four pharmaceutical products totaling 800,000 packs annually.
Lastly, the company has filed a patent application for a treatment aimed at allergic inflammation, leveraging its AI-powered Cloudscreen platform. The development reflects Cosmos Health’s ongoing commitment to addressing complex health conditions through innovative solutions. These recent developments highlight the company’s strategic efforts in expanding its product offerings and securing long-term revenue streams.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.